Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 5/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845402 | 0.92 | P2RX3 (0.43) | MAPTP2RX3KDM1AKDM4ETP53 | |
| SCHEMBL22717340 | 0.89 | P2RX3 (0.41) | MAPTPOLBP2RX3KDM1AKDM4E | |
| SCHEMBL22717413 | 0.85 | KDM1A (0.47) | MAPTPOLBP2RX3KDM1AKDM4E | |
| SCHEMBL22845221 | 0.81 | GCGR (0.40) | MAPTPOLBP2RX3KDM4EHDAC1 | |
| SCHEMBL22845220 | 0.81 | ABHD6 (0.39) | MAPTPOLBP2RX3ENPP2KDM4E | |
| SCHEMBL22718494 | 0.80 | P2RX3 (0.47) | MAPTP2RX3KDM1AKDM4ETP53 | |
| SCHEMBL22845439 | 0.76 | LMNA (0.44) | MAPTPOLBKDM4ETP53 | |
| SCHEMBL29670369 | 0.75 | P2RX3 (0.38) | MAPTP2RX3KDM1ATP53PDE10A | |
| SCHEMBL24484016 | 0.73 | P2RX3 (0.36) | MAPTPOLBP2RX3KDM1ATP53 | |
| SCHEMBL22410754 | 0.73 | P2RX3 (0.51) | MAPTP2RX3KDM1AKDM4EHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | MAPT 651/4885POLB 3198/4885P2RX3 3237/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | MAPT 651/4885POLB 3198/4885P2RX3 3237/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | MAPT 651/4885POLB 3198/4885P2RX3 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.